- Condition: Urinary Bladder, Overactive
Interventions: Drug: solifenacin succinate; Drug: fesoterodine
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Recruiting - verified May 2012 - Condition: Urinary Incontinence
Interventions: Behavioral: DVD Group; Behavioral: Bladder Health Class
Sponsors: University of Michigan; University of Michigan; National Institute of Nursing Research (NINR)
Recruiting - verified May 2012 - Conditions: Mild Cognitive Impairment; Spinal Cord Injuries
Intervention: Drug: oxybutynin, tolterodine
Sponsors: Swiss Paraplegic Centre Nottwil; Swiss Paraplegic Centre Nottwil
Recruiting - verified May 2012 - Condition: Bladder Cancer
Intervention: Drug: Gemcitabine and Cisplatin (DD GC)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Voiding Dysfunction After Pelvic Organ Prolapse Surgery
Intervention: Procedure: CISC instruction pre-operatively
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto
Not yet recruiting - verified May 2012 - Condition: Bladder Transitional Cell Carcinoma Stage IV
Interventions: Drug: Vinflunine, Gemcitabine; Drug: Vinflunine, Carboplatin
Sponsors: Pierre Fabre Medicament; Pierre Fabre Medicament
Recruiting - verified May 2012 - Condition: Vesicoureteral Reflux
Interventions: Behavioral: Parental information; Behavioral: Play therapy
Sponsors: Johns Hopkins University; Johns Hopkins University
Recruiting - verified April 2012 - Condition: Bladder Pain Syndrome
Interventions: Drug: AF-219; Drug: Sugar Pill
Sponsors: Afferent Pharmaceuticals, Inc.; Afferent Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Bladder Cancer
Interventions: Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors; Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Sponsors: Emory University; Emory University; Olympus
Not yet recruiting - verified March 2012 - Conditions: Urinary Bladder; Overactive
Interventions: Drug: Solifenacin succinate; Drug: Placebo; Behavioral: Urotherapy
Sponsors: Astellas Pharma Inc; Astellas Pharma Europe BV
Not yet recruiting - verified March 2012 - Condition: Urinary Bladder, Overactive
Interventions: Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate; Drug: fesoterodine fumarate
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Overactive Bladder
Interventions: Device: LCT-1000TM (Manufacturer: LiteCure); Device: LCT-1000TM (Manufacturer: LiteCure)
Sponsors: Zipper Urogynecology Associates; Zipper Urogynecology Associates
Recruiting - verified March 2012 - Conditions: Hematuria; Dysuria; Bladder Cancer
Intervention:
Sponsors: Medical Diagnostic Laboratories, LLC; Medical Diagnostic Laboratories, LLC
Recruiting - verified March 2012 - Condition: Urinary Bladder Tumor
Interventions: Device: Monopolar diathermy; Device: Bipolar diathermy
Sponsors: Chinese University of Hong Kong; Chinese University of Hong Kong
Recruiting - verified May 2012 - Condition: Lower Urinary Tract Symptoms
Interventions: Behavioral: Group urotherapy; Behavioral: Individual Urotherapy
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation
Not yet recruiting - verified April 2012 - Condition: Urinary Bladder, Overactive
Interventions: Procedure: Unilateral electrode placement and testing; Procedure: Bilateral electrode placement and testing
Sponsors: Centre Hospitalier Universitaire de Nīmes; Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified March 2012 - Condition: Overactive Bladder Syndrome
Intervention: Procedure: retrospective data analysis
Sponsors: University of Zurich; University of Zurich
Not yet recruiting - verified March 2012 - Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine 4 mg; Drug: Fesoterodine 8 mg; Drug: Oxybutynin; Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Not yet recruiting - verified April 2012 - Condition: Interstitial Cystitis
Intervention: Drug: TTI-1612
Sponsors: Trillium Therapeutics Inc.; Trillium Therapeutics Inc.
Recruiting - verified April 2012 - Evaluation Of Zetiq's Novel Cell Detect Technology For Detection Of Bladder Cancer In Urine CytologyCondition: Bladder Cancer Transitional Cell Carcinoma
Intervention:
Sponsors: Zetiq Technologies; Zetiq Technologies
Recruiting - verified March 2012 - Condition: Bladder Cancer
Intervention: Drug: Hexvix
Sponsors: PhotoCure; PhotoCure
Recruiting - verified March 2012 - Condition: Pain
Interventions: Drug: 88% sucrose po solution; Drug: placebo po
Sponsors: St. Justine's Hospital; St. Justine's Hospital
Not yet recruiting - verified February 2012 - Condition: Bladder Injury
Interventions: Procedure: Obturator nerve block; Procedure: Obturator nerve block
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center
Not yet recruiting - verified March 2012 - Condition: Metastatic Transitional Cell Carcinoma of the Urothelium
Intervention: Drug: BKM120
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis
Recruiting - verified March 2012 - Conditions: Neurogenic Urinary Bladder; Neurogenic Bladder Disorder; Neurogenic Dysfunction of the Urinary Bladder; Neurogenic Bladder, Uninhibited; Neurogenic Bladder, Spastic
Interventions: Drug: Investigational new drug company code: SAF312 placebo; Drug: Investigational new drug company code: SAF312
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Amputation
Intervention: Device: Pro Active Dynamic Accommodating Socket
Sponsors: Infoscitex Corporation; Infoscitex Corporation; Liberating Technologies, Inc; Telemedicine and Advanced Technology Research Center (TATRC)
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Drug: Abitren; Drug: Placebo
Sponsors: Carmel Medical Center; Carmel Medical Center
Not yet recruiting - verified March 2012 - Conditions: Healthy Subjects; Overactive Bladder
Interventions: Procedure: High resolution urodynamic assessment; Procedure: Conventional urodynamic assessment
Sponsors: Astellas Pharma Inc; Astellas Pharma Europe Ltd.
Recruiting - verified March 2012 - Conditions: Urinary Bladder, Overactive; Pelvic Organ Prolapse
Intervention: Other: Pre- and postoperative evaluations
Sponsors: Radboud University; Radboud University; Astellas Pharma Inc; Continentie Stichting Nederland (Continence Foundation The Netherlands)
Recruiting - verified January 2012 - Conditions: Overactive Bladder; Neurogenic Detrusor Overactivity
Intervention: Drug: Solifenacin succinate
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Not yet recruiting - verified February 2012 - Conditions: Liver Cirrhosis; Refractory Ascites
Intervention:
Sponsors: Sequana Medical AG; Sequana Medical AG
Not yet recruiting - verified February 2012 - Condition: Urothelial Carcinoma of the Bladder
Interventions: Radiation: Proton therapy; Radiation: IMRT
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsConditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Condition: Cystitis
Interventions: Drug: Norfloxacin; Drug: Cephalosporins; Drug: Cephalosporins
Sponsors: Eurofarma Laboratorios S.A.; Eurofarma Laboratorios S.A.
Not yet recruiting - verified February 2012 - Condition: Refractory Overactive Bladder
Intervention:
Sponsors: University of Oklahoma; University of Oklahoma
Recruiting - verified January 2012 - Condition: Patients With Pelvic Organs Prolapse
Intervention: Device: Medtronic-Dantec Urodynamic System
Sponsors: Carmel Medical Center; Carmel Medical Center
Recruiting - verified May 2012 - Condition: Neurogenic Bladder Dysfunction Nos
Interventions: Device: SpeediCath Compact; Device: Standard care
Sponsors: Coloplast A/S; Coloplast A/S
Recruiting - verified January 2012 - Condition: Neoplasm
Intervention: Genetic: SGT-94
Sponsors: SynerGene Therapeutics, Inc.; SynerGene Therapeutics, Inc.
Recruiting - verified January 2012 - Condition: Refractory Urge Urinary Incontinence
Interventions: Device: InterStim® device; Drug: Botox® injection
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Duke University; University of Alabama at Birmingham; University of California, San Diego; The Cleveland Clinic; Brown University; University of New Mexico; University of Pennsylvania; University of Pittsburgh; Oregon Health and Science University; RTI International
Recruiting - verified February 2012 - Conditions: Overactive Bladder; Overactive Urinary Bladder
Interventions: Drug: MK-4618; Drug: Tolterodine ER; Drug: MK-1468 and Tolterodine ER; Other: Placebo (MK-4618); Other: Placebo (Tolterodine ER); Drug: Prophylactic Antibiotic
Sponsors: Merck; Merck
Recruiting - verified February 2012 - Conditions: Stress Urinary Incontinence; Urgency Urinary Incontinence
Intervention: Drug: solifenacin
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Astellas Pharma Korea, Inc.
Recruiting - verified January 2012 - Condition: Infiltrating Bladder Urothelial Carcinoma
Interventions: Other: Radiation + cisplatin; Other: Radiation + cisplatin + gemcitabine
Sponsors: Centre Val d'Aurelle - Paul Lamarque; Centre Val d'Aurelle - Paul Lamarque
Recruiting - verified December 2011 - Conditions: Solid Tumors; Bladder Cancer
Interventions: Drug: Gemcitabine + Cisplatin + Dovitinib; Drug: Gemcitabine + Carboplatin + Dovitinib
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Novartis
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Drug: Genistein; Drug: Sugar pill
Sponsors: Emory University; Emory University
Not yet recruiting - verified March 2012 - Condition: Pelvic Organ Prolapse
Interventions: Procedure: Elevate Mesh; Procedure: Anterior Colporrhaphy
Sponsors: Mayo Clinic; Emanuel Trabuco; American Medical Systems
Recruiting - verified May 2012 - Condition: Pain, Postoperative
Intervention: Procedure: Pudendal nerve block
Sponsors: Diskapi Teaching and Research Hospital; Diskapi Teaching and Research Hospital
Recruiting - verified December 2011 - Conditions: Urinary Frequency; Urinary Urgency; Nocturia; Incontinence; Detrusor Uninhibited Activity; Quality of Life
Interventions: Drug: Gabapentin; Drug: Solifenacin Succinate; Drug: Placebo drugs
Sponsors: St. Luke's Medical Center, Philippines; St. Luke's Medical Center, Philippines
Recruiting - verified January 2012 - Conditions: Head and Neck Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms
Interventions: Drug: Tetrahydrouridine (THU); Drug: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Cystitis, Interstitial
Intervention:
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne
Recruiting - verified November 2011 - Condition: Bladder Cancer
Interventions: Drug: EO9 (Apaziquone); Drug: Placebo
Sponsors: Nippon Kayaku Co.,Ltd.; Nippon Kayaku Co.,Ltd.; Handok Pharmaceuticals Co., Ltd.
Recruiting - verified January 2012 - Condition: Interstitial Cystitis
Intervention: Procedure: HBOT
Sponsors: William Beaumont Hospitals; William Beaumont Hospitals
Recruiting - verified November 2011 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified May 2012 - Condition: Vesicoureteral Reflux
Intervention: Behavioral: DVD Self-Hypnosis Training Program
Sponsors: Stanford University; Stanford University; Lucile Packard Children's Hospital
Recruiting - verified November 2011 - Condition: Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
Interventions: Drug: Oxaliplatin; Drug: Oxaliplatin
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified February 2012 - Conditions: Neurogenic Incontinence; Dysfunctional Voiding
Intervention: Procedure: Division of the filum terminal
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic
Recruiting - verified November 2011 - Condition: Interstitial Cystitis
Interventions: Drug: Lidocaine Releasing Intravesical System - LiRIS®; Other: LiRIS Placebo; Procedure: Sham
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified May 2012 - Condition: Overactive Bladder
Interventions: Drug: Tarafenacin 0.2 mg; Drug: Placebo; Drug: Tarafenacin 0.4 mg
Sponsors: Kwang Dong Pharmaceutical co., ltd.; Kwang Dong Pharmaceutical co., ltd.
Recruiting - verified October 2011 - Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012 - Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerCondition: Non-muscle Invasive Bladder Cancer
Interventions: Drug: cis-UCA solution; Drug: cis-UCA solution; Drug: cis-UCA solution
Sponsors: BioCis Pharma Ltd; BioCis Pharma Ltd; Turku University Hospital; Tampere University Hospital; FinnMedi Oy
Recruiting - verified October 2011 - Conditions: Bladder Cancer; Colorectal Cancer; Endometrial Cancer; Kidney Cancer; Skin Cancer; Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Neoplasm of Lateral Wall of Urinary Bladder
Interventions: Device: Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius); Device: Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)
Sponsors: Cantonal Hospital of St. Gallen; Daniel Stephan Engeler
Not yet recruiting - verified October 2011 - Conditions: Ureteral Neoplasms; Urinary Bladder Neoplasms; Urethral Neoplasms
Interventions: Drug: Lenalidomide; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Transitional Cell Carcinoma; Bladder Cancer; Carcinoma in Situ; Carcinoma in Situ Concurrent With Papillary Tumors
Interventions: Biological: CG0070 adenovirus vector; Other: Control Arm: Quadruple Choice
Sponsors: Cold Genesys, Inc.; Cold Genesys, Inc.
Not yet recruiting - verified May 2012 - Condition: Interstitial Cystitis
Interventions: Procedure: intratrigonal injection of botulinum toxin; Procedure: cystoscopy
Sponsors: Moscow State University of Medicine and Dentistry; Moscow State University of Medicine and Dentistry
Recruiting - verified September 2011 - Conditions: Bladder Neck Obstruction; Benign Prostate Hyperplasia
Intervention: Device: Insertion of Temporary Implantable Nitinol Device (TIND)
Sponsors: Meditate; Meditate
Recruiting - verified September 2011 - Condition: Benign Prostatic Hyperplasia
Intervention: Drug: NX-1207
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified November 2011 - Condition: Urinary Bladder Neoplasms
Interventions: Biological: recMAGE-A3 + AS15 ASCI; Biological: Placebo
Sponsors: European Association of Urology Research Foundation; European Association of Urology Research Foundation; GlaxoSmithKline
Recruiting - verified September 2011 - Conditions: Febrile Neutropenia; Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Prostate Cancer; Multiple Myeloma; Bladder Cancer; B-cell Lymphoma
Intervention:
Sponsors: Sandoz; Sandoz
Recruiting - verified October 2011 - Condition: Overactive Bladder
Interventions: Drug: Solifenacin; Drug: Oxybutynin
Sponsors: Adana Numune Training and Research Hospital; Adana Numune Training and Research Hospital; Kocaeli University; Akdeniz University; Cukurova University; Baskent University; Ankara University; University of Gaziantep; Inonu University; Gaziosmanpasa University; Kahramanmaras Sutcu Imam University
Not yet recruiting - verified August 2011 - A Novel Technique For Gall Bladder Fundus Retraction In Single Incision Laparoscopic CholecystectomyCondition: Gallbladder Diseases
Intervention: Procedure: cholecystectomy
Sponsors: Mansoura University; Mansoura University
Recruiting - verified January 2011 - Condition: Painful Bladder Syndrome
Interventions: Device: quantitive sensory testing; Device: Ultrasound testing
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Not yet recruiting - verified August 2011 - Condition: Overactive Bladder
Intervention: Procedure: ECG recording
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus
Not yet recruiting - verified August 2011 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012 - Condition: Overactive Bladder
Intervention: Behavioral: Health education intervention (HEI)
Sponsors: Samsung Medical Center; Samsung Medical Center; Pfizer
Recruiting - verified January 2012 - Conditions: Bladder Cancer; Transitional Cell Carcinoma
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Urologic Oncology Group
Not yet recruiting - verified July 2011 - Conditions: Interstitial Cystitis; Painful Bladder Syndrome
Interventions: Drug: LP-08; Drug: Inactive Saline Placebo
Sponsors: Lipella Pharmaceuticals, Inc.; Lipella Pharmaceuticals, Inc.
Not yet recruiting - verified February 2012 - Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011 - Conditions: Recurrent Bladder Cancer; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder
Interventions: Drug: docetaxel; Drug: lapatinib ditosylate; Other: immunohistochemistry staining method; Genetic: fluorescence in situ hybridization; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Neurogenic Bladder; Urinary Tract Infection
Intervention: Drug: Weekly Oral Cyclic Antibiotic programme
Sponsors: University Hospital, Tours; University Hospital, Tours
Not yet recruiting - verified July 2011 - Condition: Bladder Cancer
Interventions: Drug: bacilli calmette-guerin (BCG); Drug: lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified April 2012 - Condition: Diabetes
Intervention:
Sponsors: University Hospital, Gentofte, Copenhagen; University Hospital, Gentofte, Copenhagen
Recruiting - verified May 2011 - Condition: Overactive Bladder
Interventions: Device: (VERV™ System); Device: Sham version of (VERV™ System)
Sponsors: Ethicon Endo-Surgery; Ethicon Endo-Surgery; Novella Clinical, Inc.; Data & Inference, Inc.
Recruiting - verified April 2012 - Condition: Overactive Bladder
Intervention: Drug: Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium
Sponsors: Samsung Medical Center; Samsung Medical Center; Samsung Biomedical Research Institute
Recruiting - verified December 2011 - Condition: Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Overactive Bladder
Intervention: Drug: fesoterodine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified June 2011 - Conditions: Acute Heart Failure; Acute Renal Failure
Intervention: Device: BARD® Intra-abdominal Pressure monitor
Sponsors: North Shore Long Island Jewish Health System; Staten Island University Hospital
Recruiting - verified April 2011 - Conditions: Stress Urinary Incontinence; Urge Urinary Incontinence
Intervention: Device: Transcutaneous mechanical nerve stimulation
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev; University Hospital Roskilde
Recruiting - verified February 2012 - Conditions: Urethral Neoplasms; Neoplasms, Urethral; Ureter Cancer; Cancer of the Urethra; Urethral Cancer
Interventions: Drug: Gemcitabine; Drug: Carboplatin; Drug: Lenalidomide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012 - Conditions: Urinary Bladder, Overactive; Urinary Bladder Diseases; Urologic Diseases; Urological Manifestations; Signs and Symptoms
Interventions: Drug: Solifenacin succinate and Mirabegron; Drug: Mirabegron; Drug: Solifenacin succinate; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Europe BV
Recruiting - verified April 2012 - Conditions: Breast Cancer; Colon Cancer; Bladder Cancer
Interventions: Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio Vaccine; Biological: Pneumaococcal Vaccine; Biological: Hepatitis A Vaccine; Biological: Hepatitis B Vaccine; Biological: Influenza Vaccine; Biological: PhiX 174
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Bladder Disorder, Neurogenic
Intervention:
Sponsors: Balgrist University Hospital; Balgrist University Hospital; Swiss National Science Foundation
Recruiting - verified July 2011 - Condition: Bladder Cancer
Interventions: Other: Blood sample collection; Other: urine collection
Sponsors: Christie Hospital NHS Foundation Trust; Christie Hospital NHS Foundation Trust; The Gray Institute for Radiation Oncology and Biology
Recruiting - verified April 2012 - Condition: Metastatic Urothelial Carcinoma
Intervention: Drug: Lenalidomide
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Celgene Corporation
Recruiting - verified October 2011 - Condition: Bladder Cancer
Intervention: Drug: Amrubicin
Sponsors: Mount Sinai School of Medicine; Matthew Galsky; Celgene Corporation
Recruiting - verified October 2011 - Conditions: Transitional Cell Carcinoma of Bladder; Urethra Cancer; Ureter Cancer; Malignant Tumor of Renal Pelvis
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Biological: ALT-801
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Urinary Bladder Cancer
Interventions: Drug: GemCis + Panitumumab; Drug: GemCis
Sponsors: WiSP Wissenschaftlicher Service Pharma GmbH; WiSP Wissenschaftlicher Service Pharma GmbH; Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH; Amgen
Recruiting - verified June 2011 - Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose; Drug: MK-4618 mid-low dose; Drug: MK-4618 mid-high dose; Drug: tolterodine ER; Drug: Placebo for MK-4618; Drug: Placebo for tolterodine ER; Drug: MK-4618 high dose
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Bladder Cancer
Intervention: Behavioral: Multimodal Intervention
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012 - Conditions: Painful Bladder Syndrome; Interstitial Cystitis; Pelvic Floor; Insufficiency; Bowel Dysfunction; Sexual Dysfunction; Pelvic Floor; Incompetency
Intervention: Other: Changing the Interstim parameter '' Frequency"
Sponsors: Pelvic and Sexual Health Institute; Pelvic and Sexual Health Institute
Recruiting - verified December 2011 - Conditions: Ureteral Stent Occlusion; Exposure Laser; Ureterostomy; Functional Disturbance; Vaginal Diseases; Injury of Bladder; Excessive Repair; Calculi
Intervention:
Sponsors: Hahnemann University Hospital; Hahnemann University Hospital; Baxter Healthcare Corporation
Recruiting - verified March 2011 - Conditions: Neurogenic Bladder; Urinary Retention
Intervention: Device: LoFric® catheters during clean intermittent catheterization
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital; Astra Tech AB
Recruiting - verified November 2011 - Osteopathic Manipulation for Female Interstitial Cystitis Patients With Sacroiliac Joint DysfunctionConditions: Interstitial Cystitis; Sacroiliac Joint Dysfunction
Intervention: Procedure: Osteopathic Manipulation Therapy
Sponsors: Pelvic and Sexual Health Institute; Pelvic and Sexual Health Institute; Interstitial Cystitis Association
Recruiting - verified December 2011 - Condition: Overactive Bladder
Interventions: Drug: Tolterodine ER; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Overactive Bladder; Bladder, Overactive; Overactive Urinary Bladder
Interventions: Drug: Fesoterodine 8 mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Overactive Bladder
Interventions: Drug: Fesoterodine 8mg; Drug: Fesoterodine 4mg; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Neurogenic Bladder
Intervention: Procedure: urodynamic examination
Sponsors: Balgrist University Hospital; Balgrist University Hospital
Recruiting - verified July 2011 - Condition: Bladder Outlet Obstruction
Intervention: Device: Dynamic Urine Vibration "Holter"
Sponsors: Meir Medical Center; Meir Medical Center
Not yet recruiting - verified July 2011 - Condition: Intensive Care Unit Syndrome
Interventions: Other: Measure of intravesical pressure; Other: Measure of intravesical pressure
Sponsors: Rennes University Hospital; Rennes University Hospital
Recruiting - verified November 2011 - Conditions: Neurogenic Bladder; Diseases of the Lower Urinary Tract: General Conditions
Intervention:
Sponsors: Balgrist University Hospital; Balgrist University Hospital
Recruiting - verified July 2011 - Condition: Transplantation Infection
Interventions: Drug: Cidofovir; Other: No Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Interstitial Cystitis
Interventions: Drug: Adalimumab; Other: inactive drug
Sponsors: ICStudy, LLC; ICStudy, LLC; Abbott
Recruiting - verified May 2012 - Conditions: Bladder Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Lower Urinary Tract Symptoms
Intervention: Drug: Tolterodine SR
Sponsors: Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; National Science Council, Taiwan
Recruiting - verified September 2011 - Condition: Overactive Bladder
Interventions: Drug: solifenacin; Procedure: PFMT and WBVT
Sponsors: Cantonal Hospital, Frauenfeld; Cantonal Hospital, Frauenfeld; Astellas Pharma AG, Switzerland
Recruiting - verified December 2011 - Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012 - Conditions: Bladder Cancer; Urinary Diversion
Interventions: Procedure: restrictive intraoperative fluid substitution; Procedure: assessment of the pelvic venous pressure
Sponsors: University Hospital Inselspital, Berne; University Hospital Inselspital, Berne
Recruiting - verified February 2012 - Conditions: Stroke; Catheter Associated Urinary Tract Infection
Intervention: Behavioral: Nursing protocol to avoid Foley catheter placement
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified March 2012 - Condition: Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy.
Intervention: Drug: Pazopanib as add-on to vinflunine
Sponsors: Lukas-Krankenhaus GmbH; Prof. Dr. Thomas Otto
Recruiting - verified January 2012 - Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012 - Conditions: Neurogenic Bladder; Spina Bifida
Intervention: Device: Intermittent catheterization
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011 - Condition: Bladder Cancer
Intervention: Drug: Everolimus and Intravesical Gemcitabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Carcinoma, Non-Small-Cell Lung; Urinary Bladder Neoplasms
Intervention: Drug: Carbon-14-labeled carboplatin
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified December 2011 - Conditions: Pelvic Pain; Abdominal Pain; Painful Bladder Syndrome; Interstitial Cystitis; Irritable Bowel Syndrome
Intervention: Other: Chronic pelvic pain
Sponsors: Copenhagen University Hospital at Herlev; Copenhagen University Hospital at Herlev
Recruiting - verified October 2010 - Condition: Urothelial Carcinoma
Intervention: Drug: Gemcitabine and Cisplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Condition: Over Active Bladder
Intervention: Drug: Fesoterodine
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Bladder Carcinoma; Infiltrative Bladder Carcinoma; Cystectomy
Intervention: Drug: LAPATINIB
Sponsors: University Hospital, Bordeaux; University Hospital, Bordeaux
Recruiting - verified November 2011 - Condition: Incontinence, Overactive Bladder, Stress Urinary Incontinence
Intervention:
Sponsors: Ludwig-Maximilians - University of Munich; Ludwig-Maximilians - University of Munich
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Urothelial Carcinoma
Interventions: Drug: AEZS-108; Drug: AEZS-108 at MTD
Sponsors: AEterna Zentaris; AEterna Zentaris; University of Miami; Miami VA Healthcare System; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified June 2011 - Condition: Carcinoma, Transitional Cell
Intervention: Drug: Tesetaxel
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified November 2011 - Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Interstitial Cystitis; Painful Bladder Syndrome; Pain
Interventions: Drug: Oxycodone naloxone prolonged release tablets; Drug: Placebo tablets
Sponsors: Mundipharma Research GmbH & Co KG; Mundipharma Research GmbH & Co KG
Recruiting - verified February 2012 - Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Overactive Detrusor; Neurogenic Bladder
Intervention: Drug: Oxybutynin
Sponsors: Watson Pharmaceuticals; Watson Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: vandetanib; Drug: Placebo
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Condition: Urethral Strictures
Intervention: Procedure: Internal Urethrotomy
Sponsors: Sheba Medical Center; Sheba Medical Center
Recruiting - verified August 2011 - Conditions: Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer
Intervention: Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Interstitial Cystitis
Interventions: Drug: Dexmedetomidine; Drug: Normal Saline
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011 - Condition: Gall Bladder Diseases
Interventions: Procedure: NOTES Cholecystectomy; Procedure: Laparoscopic Cholecystectomy
Sponsors: Natural Orifice Surgery Consortium for Assessment and Research; Natural Orifice Surgery Consortium for Assessment and Research; American Society for Gastrointestinal Endoscopy
Recruiting - verified November 2011 - Condition: Overactive Bladder
Interventions: Drug: Liposome encapsulated botulinum toxin A; Drug: Normal saline instillation
Sponsors: Buddhist Tzu Chi General Hospital; Buddhist Tzu Chi General Hospital; Department of Health, Taiwan
Recruiting - verified August 2011 - Condition: Bladder Cancer
Intervention: Drug: SCH 721015
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified February 2012 - Condition: Vesicoureteral Reflux
Intervention:
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center
Recruiting - verified June 2011 - Condition: Urinary Bladder, Overactive
Interventions: Drug: AGN-214868; Drug: AGN-214868; Drug: AGN-214868; Drug: AGN-214868 placebo; Drug: AGN-214868; Drug: AGN-214868
Sponsors: Allergan; Allergan
Recruiting - verified April 2012 - Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Vesicoureteral Reflux
Intervention:
Sponsors: Children's Research Institute; Children's Research Institute
Not yet recruiting - verified April 2012 - Conditions: Recurrent Bladder Cancer; Stage 0 Bladder Cancer; Stage I Bladder Cancer; Stage II Bladder Cancer; Transitional Cell Carcinoma of the Bladder
Interventions: Dietary Supplement: broccoli sprout extract; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012 - Conditions: Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
Interventions: Drug: Pazopanib (GW786034); Drug: Paclitaxel
Sponsors: Stanford University; Sandy Srinivas; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Bladder Cancer
Intervention: Other: external radiation therapy with gemcitabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012 - Conditions: Interstitial Cystitis; Chronic Prostatitis
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified December 2011 - Condition: Spina Bifida
Intervention: Procedure: Nerve Rerouting
Sponsors: William Beaumont Hospitals; William Beaumont Hospitals; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified March 2012 - Condition: Urothelial Carcinoma
Intervention: Procedure: optimal TURB
Sponsors: Clinique Mutualiste Chirurgicale de la Loire; Clinique Mutualiste Chirurgicale de la Loire
Recruiting - verified April 2012 - Conditions: Vaginal Vault Prolapse; Enterocele; Uterine Prolapse; Cystocele; Rectocele
Interventions: Device: Elevate mesh; Device: Sacrocolpopexy
Sponsors: Hospital Clinic of Barcelona; Francisco Carmona; American Medical Systems
Recruiting - verified March 2012 - Conditions: Fibromyalgia; Irritable Bowel Syndrome; Fatigue Syndrome, Chronic
Intervention:
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University of Colorado, Denver
Recruiting - verified December 2011 - Condition: Overactive Bladder
Interventions: Drug: Trospium Chloride (Sanctura XR); Drug: Over-encapsulated Placebo
Sponsors: Allergan; Allergan
Recruiting - verified March 2012 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Condition: Bladder Cancer
Intervention: Device: Neo-Urinary Conduit
Sponsors: Tengion; Tengion
Recruiting - verified January 2012 - Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010 - Conditions: Cystocele; Uterine Prolapse
Intervention: Device: TiLOOP® Total 6 (Surgical mesh implantation)
Sponsors: pfm medical ag; pfm medical ag; Aix Scientifics; GfE Medizintechnik GmbH
Recruiting - verified May 2012 - Condition: Bladder Cancer
Interventions: Procedure: open radical cystectomy; Procedure: robotic-assisted radical cystectomy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011 - Conditions: Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Intervention: Drug: single arm dose dense MVAC
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified March 2012 - Condition: Overactive Bladder in Parkinson's Disease
Interventions: Drug: solifenacin succinate (VESIcare); Drug: placebo
Sponsors: University of South Florida; University of South Florida; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Genentech
Recruiting - verified December 2011 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: Bacillus Calmette-Guerin (BCG)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012 - Conditions: Urinary Bladder, Overactive; Osteoporosis
Interventions: Other: Micturition diary; Other: Hospital Anxiety and Depression scale; Other: EuroQol-5D; Other: Self-consciousness questionnaire
Sponsors: Maastricht University Medical Center; Maastricht University Medical Center
Recruiting - verified July 2011 - Condition: Bladder Neoplasms
Intervention: Radiation: Radiation boost
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital
Recruiting - verified March 2012 - Condition: Bladder Cancer
Intervention: Drug: OGX-427
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health; NCIC Clinical Trials Group; Vancouver General Hospital Foundation
Recruiting - verified February 2012 - Conditions: Cystitis; Bladder Diseases
Intervention: Drug: Cidofovir
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Gilead Sciences
Not yet recruiting - verified March 2012 - Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Advanced Malignancies
Intervention: Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified November 2011 - Conditions: Overactive Bladder; Benign Prostatic Hyperplasia
Intervention: Drug: doxazosin plus tolterodine SR
Sponsors: Samsung Medical Center; Samsung Medical Center
Recruiting - verified December 2011 - Conditions: Interstitial Cystitis; Painful Bladder Disorder
Interventions: Drug: Oxytocin; Other: Saline as a nasal spray
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified March 2012 - Condition: Vesico-vaginal Fistula
Intervention: Device: Surgisis Biodesign (Vesico-vaginal fistula plug)
Sponsors: Cook; Cook
Recruiting - verified December 2011 - Conditions: Urinary Catheterization; Multiple Sclerosis
Interventions: Device: LoFric Primo + Anticholinergic medication; Drug: Anticholinergic medication
Sponsors: Astra Tech AB; Astra Tech AB
Recruiting - verified August 2011 - Condition: Cancer
Interventions: Procedure: ultrasound hyperthermia treatment; Radiation: brachytherapy
Sponsors: National Cancer Institute (NCI); University of California, San Francisco; National Cancer Institute (NCI)
Recruiting - verified May 2009 - Condition: Painful Bladder Syndrome
Intervention: Other: Physical examination
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Washington University School of Medicine
Recruiting - verified April 2012 - Conditions: Urothelial Cancer; Renal Pelvis Cancer; Ureter Cancer; Bladder Cancer
Interventions: Other: saliva sample and questionaire; Other: saliva sample, questionaire
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Conditions: Bladder Cancer; Cancer; Bladder Neoplasms; Urinary Bladder Cancer
Intervention:
Sponsors: Lahey Clinic; Lahey Clinic
Recruiting - verified June 2011 - Conditions: Bladder Cancer; Bladder Neoplasms
Intervention:
Sponsors: Lahey Clinic; Lahey Clinic
Recruiting - verified June 2011 - Condition: Bladder Exstrophy
Intervention:
Sponsors: Connecticut Children's Medical Center; Connecticut Children's Medical Center
Recruiting - verified June 2011 - Condition: Overactive Bladder
Interventions: Drug: Tolterodine extended-release (ER) 4mg; Drug: Placebo
Sponsors: Samsung Medical Center; Samsung Medical Center; Pfizer
Recruiting - verified May 2009 - Condition: Bladder Cancer
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified March 2012 - Condition: Cancer
Interventions: Drug: hydroxychloroquine; Drug: sunitinib malate
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Conditions: Bladder Cancer; Cervical Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Leukemia; Liver Cancer; Lung Cancer; Pancreatic Cancer; Tobacco Use Disorder
Interventions: Drug: nicotine; Drug: varenicline; Other: placebo
Sponsors: Butler Hospital; Butler Hospital; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive BladderCondition: Overactive Bladder
Interventions: Behavioral: Dietary Caffeine reduction; Drug: Anticholinergic medication
Sponsors: IWK Health Centre; IWK Health Centre
Recruiting - verified July 2011 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Pancreatic Cancer; Gastrointestinal Neoplasms; Colon Rectal Cancer Adenocarcinoma; Esophageal Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastrooesophageal Cancer; Gastrointestinal Stromal Tumor (GIST); Hepatobiliary Neoplasm; Liver Carcinoma; Gallbladder Carcinoma; Bile Duct Carcinoma; Carcinoma of the Large Intestine; Anal Cancer
Intervention: Procedure: Observation
Sponsors: Stanford University; Stanford University
Recruiting - verified June 2011 - Condition: Bladder Cancer
Interventions: Radiation: PCI; Other: Brain X-ray
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011 - Condition: Pyelonephritis
Interventions: Drug: Trimethoprim Sulfamethoxazole; Drug: placebo
Sponsors: University of Alberta; University of Alberta; Canadian Urological Association
Recruiting - verified September 2011 - Condition: Bladder Cancer
Intervention: Behavioral: Quality Of Life questionnaires
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified March 2012 - Conditions: Spinal Cord Injury; Neurogenic Bladder; Urinary Tract Infection
Interventions: Other: Shortened course of antibiotic therapy; Other: Standard Therapy
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified April 2012 - Condition: Neurogenic Detrusor Overactivity
Interventions: Drug: Darifenacin; Drug: Darifenacin; Drug: Darifenacin; Drug: Darifenacin
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified May 2012 - Condition: Transitional Cell Carcinoma
Intervention: Drug: Paclitaxel
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Celgene Corporation
Recruiting - verified July 2011 - Conditions: Prostatitis; Cystitis, Interstitial; Urinary Bladder, Overactive; Chronic Pelvic Pain Syndrome; Painful Bladder Syndrome
Intervention:
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011 - Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome; Chronic Bacterial Prostatitis; Asymptomatic Inflammatory Prostatitis; Painful Bladder Syndrome; Cystitis, Interstitial
Intervention: Genetic: Genomic and proteomic biomarker discovery
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center
Recruiting - verified June 2011 - Condition: Bladder Cancer
Interventions: Drug: Methotrexate; Drug: Vinblastine; Drug: Doxorubicin; Drug: Cisplatin; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: Hellenic Oncology Research Group; Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified March 2012 - Condition: Superficial Bladder Cancer
Intervention: Biological: DTA-H19/PEI
Sponsors: BioCancell Therapeutics Israel Ltd.; BioCancell Therapeutics Israel Ltd.
Recruiting - verified May 2012 - Condition: Bladder Cancer
Intervention: Drug: Paclitaxel, nanoparticle albumin-bound
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012 - Condition: Bladder Cancer
Interventions: Other: Computed Tomography Urography (CTU); Other: Intravenous Urography (IVU)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GE Healthcare
Recruiting - verified April 2012 - Conditions: Chronic Prostatitis (CP); Chronic Pelvic Pain Syndrome (CPPS); Painful Bladder Syndrome (PBS); Benign Frequency Syndrome (BFS); Benign Daytime Frequency Syndrome (BDFS)
Intervention:
Sponsors: Children's Hospital Boston; Children's Hospital Boston; National Institutes of Health (NIH)
Recruiting - verified July 2011 - Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Overactive Bladder
Interventions: Biological: botulinum toxin Type A 200U; Biological: botulinum toxin Type A 300U; Biological: placebo; botulinum Toxin Type A 200U; Biological: Placebo; botulinum toxin Type A 300U
Sponsors: Allergan; Allergan
Recruiting - verified December 2011 - Conditions: Vesico-Ureteral Reflux; Urinary Tract Infections
Interventions: Drug: Trimethoprim-Sulfamethoxazole; Drug: Placebo
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012 - Conditions: Interstitial Cystitis; Painful Bladder Syndrome; Chronic Pelvic Pain Syndrome
Intervention:
Sponsors: Children's Hospital Boston; Children's Hospital Boston; National Institutes of Health (NIH)
Recruiting - verified July 2011 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: eribulin mesylate; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Join Clinical trials for Bladder cancer |
